NImmune was launched in early 2023 to develop omilancor, NIM-1324, and the entire LANCL portfolio, which it has bought from Landos Biopharma.

The company will move towards Phase III trials of omilancor in ulcerative colitis, with the goal of exploring follow-on development in Crohn’s disease  and psoriasis.